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Abstract
Background—HIV transmission risk during acute and early HIV infection (EHI) is sharply
elevated, but the contribution of EHI to ongoing HIV transmission is controversial. However, in
settings where EHI contributes substantially to secondary transmissions, early diagnosis and
intervention may be critical for HIV prevention. We estimated the contribution of EHI to HIV
incidence in Lilongwe, Malawi and predicted the future impact of hypothetical prevention
interventions affecting EHI only, chronic HIV infection (CHI) only, or both stages.
Methods—We developed a deterministic mathematical model describing heterosexual HIV
transmission, informed by detailed behavioural and viral load data collected in Lilongwe. We
included sexual contact within and outside steady pairs and divided the infectious period into
multiple intervals to allow for changes in transmissibility by infection stage. We used a Bayesian
melding approach to fit the model to HIV prevalence data collected over time at Lilongwe
antenatal clinics. We evaluated interventions that reduced the per-contact transmission probability
to 0·00003 in those receiving them and varied the proportion of individuals receiving the
intervention in each stage.
Findings—We estimated that 38·4% (95% credible interval: 18·6%-52·3%) of ongoing HIV
transmissions in Lilongwe are attributable to sexual contact with EHI index cases. Interventions
acting only during EHI substantially reduced HIV prevalence, but did not lead to elimination, even
with 100% coverage. Interventions acting only during CHI also reduced HIV prevalence, but
coverage levels of 95%-99% were required to move the epidemic toward elimination. In scenarios
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with <95% CHI coverage, additional interventions reaching 25%-75% of EHI cases reduced HIV
prevalence substantially.
Interpretation—Our results suggest that EHI plays an important role in HIV transmission in this
sub-Saharan African setting. Without near-perfect coverage, interventions during CHI will likely
have incomplete effectiveness unless complemented by strategies targeting the heightened
transmission risk of EHI.
Introduction
Acute HIV infection (AHI) is the period between HIV acquisition and the development of
detectable antibodies against the virus. Early HIV infection (EHI), including AHI, is
characterized by rapid viral replication, intense immune response and immune destruction,
and viral diversification.1 Phenotypic factors unique to the founder virus(es) causing
infection,2 along with exceptionally high viral loads,3, 4 result in greater transmission risk
during EHI.5-8
The population-level effect of transmission prevention efforts during EHI will vary across
settings, depending on the contribution of EHI cases to epidemic spread. Estimates of this
contribution have varied widely,6, 9-18 depending on site-specific factors such as risk
behaviour patterns and the local epidemic stage. Recently, a strategy to use mass
antiretroviral treatment to stop the spread of HIV-1 has gained considerable attention.19 The
“test and treat” strategy advocates regular, widespread HIV testing and immediate initiation
of antiretroviral therapy (ART) for infected persons, based on the premise that ART-induced
reductions in viral load will decrease infectiousness. However, the effectiveness of this
approach will depend, in part, on the role of EHI in ongoing transmission. Where EHI has a
major role, the effectiveness of test-and-treat strategies will likely be limited unless patients
with EHI can be detected and included. A recent mathematical modelling exercise19 that has
sparked extensive controversy20-29 concluded that an annual test-and-treat strategy could
eliminate HIV, but EHI was not rigorously addressed in this model.22, 24, 25
In this study, we estimate the contribution of EHI to HIV spread in Lilongwe, Malawi,
where HIV-1 is hyperendemic and transmission is almost entirely through heterosexual
contact. We also examine the population-level impact of prevention interventions affecting
only EHI, only chronic (post-“early”) HIV infection (CHI), or both EHI and CHI, with a
particular emphasis on estimating the impact of an annual test-and-treat strategy.19 To
address these aims, we used empirical data from our studies in Lilongwe3, 30 to develop a
mathematical model describing heterosexual HIV transmission. The results suggest that EHI
plays an important role in the ongoing spread of HIV in Malawi, and that involvement of
people with EHI will be required for maximal HIV prevention.
Methods
Modelling analyses proceeded in five steps (Figure 1): defining the model structure and
equations (Step 1); conducting a Bayesian melding procedure to identify model parameter
values most compatible with observed epidemic dynamics, given prior estimates for
biological and behavioural parameters (Steps 2-4); and estimating the contribution of EHI
and predicted intervention effects (Step 5). We describe our methods briefly below, with
additional details in the Web Appendix.
Model structure
We constructed a compartmental, deterministic model explicitly describing heterosexual
partnership formation and dissolution (Figure 2). Following previous modifications15 on the
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classic pair-formation model,31 sexual contact was assumed to occur: 1) at a constant
frequency within steady partnerships, 2) as casual, one-off contacts by paired individuals
outside of steady partnerships, and 3) as casual, one-off contacts by unpaired individuals
(singles). This structure captures phenomena that are important in the context of time-
varying HIV infectivity: HIV is “trapped” within a pair while each infected member is
monogamous, but HIV can “escape” upon partnership dissolution or sexual contact outside
the pair. Additionally, pairs of uninfected individuals are “sheltered” from HIV while each
partner is monogamous, but HIV can “enter” through outside contacts. Long-term
concurrency is not captured, but the model allows consecutive partnerships and sporadic
concurrency. Our data from Lilongwe suggest that long-term monogamy predominates in
this population, with a minority engaging in narrowly spaced consecutive partnerships,
sporadic concurrency, or long-term concurrency.30 Individuals entered the model as singles,
and exited after an average sexual lifespan of 35 years, with additional AIDS-related
mortality in the final infection stage.
To capture variation in transmission probabilities over time, we divided HIV into EHI,
asymptomatic HIV, early AIDS, and late AIDS. We defined EHI as the initial one- to six-
month period of elevated infectivity, based on the best available estimates of transmission
rates by infection stage,6 calculated among HIV-serodiscordant couples in Rakai, Uganda.5
We divided this period into five intervals to allow changes in transmission probabilities
related to evolving viral loads. Intervals 1-4 were each one week in duration to capture the
initial viral load changes.3 We sampled interval 5 from a uniform distribution of 1·4 weeks
to 5 months, corresponding to the total assumed EHI duration of ~1 to ~6 months.6 We
represented the asymptomatic period as three equal intervals (intervals 6-8) of 1·8 to 3·2
years each to approximate observed survival time distributions in untreated cases.32 We
based the durations of “early AIDS” (interval 9) and “late AIDS” (interval 10) on the Rakai
analyses, specifying normal distributions with mean 0·75 year and 0·83 year, respectively.6
As an additional extension, we stratified the model population into two groups to
accommodate sexual behaviour heterogeneity. The prior distributions that we specified
corresponded to the “lower-risk group” having longer partnerships and lower rates of sexual
contact by singles than the “higher-risk group.” Individuals remained in one risk group and
steady pairs were formed within groups. However, one-off contacts with casual partners
were chosen without risk-group restrictions. The model allowed for increased HIV
transmission probabilities for contacts with higher-risk partners, representing an assumed
greater likelihood of transmission-amplifying cofactors, such as ulcerative sexually
transmitted infections (STIs) or anal intercourse. Sexual behaviour parameters were held
constant across infection status/stage categories. The model is readily adaptable to other
settings with predominately heterosexual or homosexual transmission; adaptation to settings
where parenteral transmission plays a large role is more complex.
Statistical analyses
We used a Bayesian melding approach32, 33 to fit the model to empirical HIV prevalence
data and to account for uncertainty in model inputs and outputs (Figure 1). This approach
combines prior information about inputs (e.g., sexual behaviour, transmission probabilities)
with data about a primary output (HIV prevalence). Sources of prior information on inputs
are described below. For data on model output, we used HIV prevalence estimates from
Lilongwe antenatal clinics (ANC) over the period 1987-2005.34 We implemented a sample-
importance-resample algorithm to identify the input parameter values producing epidemic
curves most closely matching ANC data. Briefly, we ran 100,000 model simulations,
sampling randomly from the prior distributions of all input parameters in each simulation.
Next, we weighted each simulation according to its likelihood-based compatibility with
ANC data, and then we resampled (with replacement) from the simulations, with probability
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of selection proportional to the assigned weight. Under this approach, the simulation
resampled most frequently (the mode) is the best-fitting simulation (i.e., the most compatible
with empirical HIV prevalence data). The 2·5th and 97·5th percentiles were used to obtain
95% credible intervals (CrI) for model parameters and output.
We used the Runge-Kutta 4 algorithm in Berkeley Madonna 8·0·1 (Berkeley, California,
USA) to solve the model numerically. We performed statistical and graphical analyses with
SAS 9·1 (SAS Institute, Cary, North Carolina, USA), Stata 9 (StataCorp, College Station,
Texas, USA), and R.
Parameter values
We based the initial size of the adult (ages 15-49) population on census data35 (Table 1), and
sampled uniformly in the range 1960-1985 for the year of the first HIV case in Lilongwe,
reflecting the uncertainty around this time.
We based the per-contact transmission probability for asymptomatic HIV, along with
transmission co-factor effects, on meta-analysis estimates.7, 8 We allowed the transmission
co-factor effect to range from 1 (no transmission amplification) to 6 (per-contact
transmission probability 6 times as high in the higher-risk group than in the lower-risk
group). The upper bound was based on estimates for the co-factor effect of concomitant
STIs,7, 8 but could also broadly represent other co-factors, such as the possibility of some
contacts being anal rather than vaginal. To calculate per-contact transmission probabilities
for EHI and early AIDS, we multiplied the asymptomatic-period estimate by the
transmission rate ratios comparing EHI and early AIDS to asymptomatic infection in Rakai
(Table 1).6 We then used longitudinal viral load data from AHI cases in Lilongwe,3 along
with transmission rates according to viral load,36 to estimate separate transmission
probabilities within each EHI interval, subject to the constraint that the weighted average
transmission probability across intervals equaled the overall EHI-period average. To match
the lack of transmission events observed during late AIDS in the Rakai data (likely due to
ceasing of sexual activity due to illness),6 we set the per-contact transmission probability for
this period to 0.
We estimated sexual behaviour parameters from data we collected at Kamuzu Central
Hospital STI Clinic in Lilongwe.3, 30 These data included detailed information about
partnership durations and contact frequency by marital status and partner type.
Estimating proportion new infections from EHI
We calculated the annual proportion of new infections attributable to EHI transmitters from
model equations tracking cumulative infections by calendar time and index infection period.
Predicting intervention effects by stage of initiation
We explored the potential effects of an HIV prevention intervention that was assumed to
dramatically decrease the per-contact transmission probability in all contacts affected by the
intervention. Such an intervention could be strictly behavioural (e.g., 100% condom use by
the male partner), strictly biological (e.g., ART use by infected cases), or a combination of
the two. The per-contact transmission probability in such contacts was reduced to 0·000033.
This value is the midpoint of male-to-female and female-to-male transmission probabilities
estimated under ART-induced viral suppression,37 but can also approximate effective
condom use or other highly effective interventions. The intervention was not assumed to
affect pair formation or dissolution rates, nor the frequency of sexual contact within or
outside of steady partnerships. We varied the intervention coverage in each period, i.e., the
proportion of cases (0%, 25%, 50%, 75%, 85%, 90%, 95%, 100%) in whom transmission
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probabilities were successfully reduced, to explore scenarios with intervention effects during
EHI only (as a benchmark), CHI only, or both EHI and CHI.
To compare the maximum possible benefits of interventions in each period, we assumed that
interventions began early in a given period. Interventions during EHI were assumed to start
in week 3 and to end at the start of CHI. This assumption, which is based on our experience
with AHI detection in Lilongwe,3 allows for blood collection in the second week of
infection and an additional week to report positive HIV RNA or p24 results. Interventions
acting in CHI were assumed to start at the beginning of the earliest CHI interval (interval 6)
and continue through AIDS. Although this assumption reflects HIV diagnosis earlier than
most current diagnoses,38 it approximates the time at which a highly effective test-and-treat
program with annual HIV antibody tests would detect cases.19 Under such a strategy,
infected individuals would be detected (on average) ~6 months into infection, approximately
the time at which CHI starts in our model.
Interventions were assumed to begin in 2010 (at a mature epidemic phase). Our main
intervention effect measures were the predicted HIV prevalence and incidence over the
years 2010-2040. We also calculated the levels of coverage required for “elimination” of
HIV during this time frame, using two separate definitions: 1) the “Granich definition”
(reduction in annual incidence to less than 1 case per 1000 persons);19 and 2) the “Dahlem
definition” (reduction in annual incidence to 0 cases), developed at the WHO-sponsored
Dahlem Workshop on the Eradication of Infectious Diseases.39 As a complementary
analysis, we predicted the percentage of new infections averted between 2010 and 2015.
As intervention effects on index case life expectancy could range from minimal (with
strictly behavioural interventions) to substantial (with ART), we modelled two extremes of
CHI interventions: a) no effect on infection duration, and b) increased average infection
duration by ~10 to ~15 years.19, 40 The life expectancy increase in the latter scenario is
based on survival-time estimates for individuals starting ART at the beginning of CHI.19, 40
Therefore, the CHI-only intervention with increased life expectancy approximates an annual
test-and-treat strategy.
For base-case analyses, we used the modal input parameters. To explore intervention effects
in situations with a greater or lesser importance of EHI, we used the input parameters
producing the upper and lower 95% credible limits of the proportion of new cases
attributable to EHI in 2010.
Additional sensitivity and influence analyses (described in more detail in Web Appendix)
To consider intervention effects under a variety of alternate conditions, we conducted
analyses with greater assumed life expectancy increases among those receiving ART, as
well as later intervention starts within EHI and/or CHI. We also explored the individual
influence of each input parameter on results, examined epidemic dynamics within the high-
risk and low-risk groups separately, and considered a model in which sexual behaviour
parameters could change over the course of the epidemic.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The corresponding author had full access to all data
in the study and had final responsibility for the decision to submit for publication.
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Model Fit to HIV Prevalence Data
The Bayesian melding procedure yielded a posterior distribution of 380 unique epidemic
curves in good agreement with the ANC data used to define HIV prevalence in Lilongwe
(Figure 3). From the modal simulation, we estimated that HIV prevalence in Lilongwe’s
general adult population peaked at 24·7% in 1996, declined to 17·3% in 2005, and is
currently 14·3%. ANC prevalence estimates peaked at 27·0% (95% confidence interval:
22·7%, 31·6%) in 1996 and declined to 18·6% (95% confidence interval: 16·0%, 21·3%) at
the most recent survey in 2005.
The parameters producing the best fit to ANC data included an estimate that 40% of the
population was in the initial “high-risk” group (Table 1); this proportion decreased to ~20%
as the epidemic progressed. The best-fitting partnership durations were 2·5 years and 1·3
months in the low-risk and high-risk groups, respectively, with gaps of 1·5 years and 11
days between partners. Per-contact transmission probabilities were five times as great in the
higher-risk versus lower-risk group (Table 1), representing transmission co-factor effects.
For most input parameters (e.g., viral load, transmission probabilities), the specified prior
distributions were similar to the posterior distributions resulting from the fit to empirical
data (see Web Appendix). The model fit was most informative for the size of the high-risk
group, transmission co-factor effects, and high-risk pair formation and dissolution rates.
Estimated EHI contribution and related parameters
Based on the model results, 38·4% (95% CrI: 18·6%, 52·3%) of incident HIV infections
resulted from contact with a partner with EHI in 2010 (Figure 4). The best-fitting EHI
duration was 4·8 months (95% CrI: 1·6, 5·8) (Table 1). The best-fitting transmission rate
ratio comparing EHI to asymptomatic chronic infection was 30 (95% CrI: 14, 47); that is,
the weighted average per-contact transmission probability during EHI was 30 times as high
as during asymptomatic infection (Table 1). The modal transmission rate ratio, in
conjunction with other modal parameters, corresponds to per-contact transmission
probabilities during EHI ranging from 3/1000 to 4/100 in the low-risk group (Table 1), and a
cumulative transmission probability during EHI of ~26% within low-risk, HIV-discordant
pairs (result not shown in Table 1).
Intervention effects
Biological or behavioural interventions assumed to sharply reduce HIV transmission
probabilities during EHI (with no residual effect thereafter) were predicted to substantially
reduce HIV prevalence in Lilongwe, but not to result in HIV elimination, even when 100%
of EHI cases received the intervention (Figure 5A, solid green line). As the EHI-only
intervention was not assumed to affect life expectancy, changes in HIV prevalence (Figure
5A) and incidence (Figure 5B) were similar.
In several scenarios, lifelong CHI-only interventions initiated ~6 months after infection were
predicted to have greater effects on HIV prevalence and incidence than EHI-only
interventions, but results were sensitive to assumptions about life expectancy (Figures
5C-5F). HIV elimination within 30 years under the “Dahlem definition” (reduction in annual
incidence to 0 cases39) was not possible at any CHI-only coverage level, and elimination
under the “Granich definition” (reduction in annual incidence to less than 1 case per 1000
persons19) was only possible with 95% or 99% CHI-only coverage, assuming no life
expectancy increase or a 10-15-year increase, respectively (Figure 6). If the intervention was
assumed to increase life expectancy (e.g., treatment as prevention19, 41), CHI-only coverage
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levels of 75% or less were predicted to increase HIV prevalence above the level that would
be expected with no intervention (Figure 5E).
The combination of EHI and CHI interventions reduced HIV prevalence and incidence
substantially, even if CHI intervention coverage was only 75%-85% (Figures 5G-5N, dotted
lines). Though the intervention coverage in each stage required for elimination depends on
the definition of elimination and the intervention effects on life expectancy (Figure 6), the
combination of results shown in Figures 5 and 6 suggests that if very high levels of coverage
(i.e., ≥95%) cannot be attained with a CHI-only intervention, then the addition of EHI
interventions will be necessary to sustainably reduce HIV prevalence and incidence in
Lilongwe.
We observed these same patterns in sensitivity analyses where EHI was assumed to
contribute 18·6% or 52·3% (our lower and upper 95% credible limits) of ongoing
transmissions. Complementary analyses of infections averted showed similar trends.
Sensitivity analyses in which CHI interventions increased life expectancy by 10-20
additional years provided further support for inclusion of EHI interventions, as did analyses
where CHI interventions were assumed to start ~2 years – rather than ~6 months – into
infection. (See Web Appendix for results of sensitivity analyses and other complementary
analyses.)
Discussion
The magnitude of the HIV epidemic in sub-Saharan Africa has been difficult to explain. One
explanation for the extensive spread of HIV emphasizes the importance of persons with
acute and early HIV infection, who are highly infectious but rarely aware of their infection
status.42 Amplified transmission in this stage of infection has been ascribed to high viral
loads3, 4 and an apparent increase in viral infectivity.43 In rhesus macaques, the ratio of
infectious virions to total virions is up to 750 times as high during AHI as during CHI.43 In
Ugandan HIV-serodiscordant couples, transmission rates were approximately 25 times as
high during early versus asymptomatic infection.6 Phylogenetically-defined infection
clusters16-18, 44 and documented acute-to-acute transmission events45, 46 further support the
potential importance of early infection.
We undertook the current study to understand the contribution of EHI to the HIV epidemic
in Lilongwe, Malawi, where we have conducted studies to identify patients with AHI,47-49
characterize their sexual behaviours,50 and measure viral load changes during EHI.3 We
estimated that EHI index cases are responsible for 19%-52% of HIV transmissions in
Lilongwe, with a mode of 38%. Our results suggest that the initial period of elevated
transmissibility may be fairly long (~5 months), and that transmissibility during EHI is 30
times as great as during CHI.
Mathematical modelling estimates of the importance of EHI have varied
widely, 6, 9, 10, 12-15, 31, 51 due in part to differing assumptions and a paucity of data for
parameter definitions. Endemic-phase estimates of the proportion of new infections due to
EHI in sub-Saharan Africa have ranged from 7% to 31% in modelling studies.6, 13
Phylogenetic studies conducted among MSM or mixed populations in western settings have
estimated that 25%-49% of incident infections are due to EHI.16-18, 44
A strength of our model is the extensive use of local data for model parameterization. We
used sexual behaviour data from Lilongwe30 to define contact patterns specific to the setting
of interest and viral load data from AHI patients in Lilongwe3 to provide high resolution in
the time-course of transmission probabilities during EHI. We fitted the model to local HIV
prevalence data using a Bayesian melding approach. The close parameterization of the
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model based on data from the setting of interest allows us to expect results with greater
reliability and applicability – at least in Lilongwe and similar settings – than could be
expected from a model using a combination of parameter values derived from disparate
populations.
Our model was enhanced in several other ways in comparison to previous models addressing
AHI/EHI. To model contact patterns relevant to HIV transmission, we explicitly
incorporated both steady pairs and casual contacts, with consideration of both high-risk and
low-risk groups. The Bayesian melding approach allowed us to account for input and result
uncertainty. Finally, we conducted sensitivity analyses to assess intervention effects under a
range of predicted EHI contributions.
The idea of using ART as a transmission prevention strategy has gained remarkable
attention.19, 41 This idea emerges from the reduction of HIV replication in the genital tracts
of persons on ART,52, 53 and apparent suppression of HIV transmission in serodiscordant
couples when the index case receives ART.54-56 A widely cited mathematical model has
concluded that annual test-and-treat strategies could virtually eliminate the epidemic in
South Africa,19 but the importance of EHI appears to have been underestimated in that
model,22, 24, 25 and other modelling studies examining the potential benefits of ART have
been less optimistic about the test-and-treat approach.57, 58
Accordingly, we examined the effects of behavioural and/or biomedical interventions that
might drastically reduce sexual transmission at different stages of HIV. One such
intervention was assumed to improve survival and reduce transmissibility from the onset of
CHI, approximating an annual test-and-treat strategy.19 Our results suggest that even highly
effective behavioural and/or biological interventions – including “test-and-treat” – are
unlikely to eliminate HIV in Lilongwe and similar settings unless people with EHI are
included. Even if the contribution of EHI to ongoing transmission is as low as ~20% (the
lower credible limit in our analysis), intervention only during CHI is unlikely to eliminate
HIV unless nearly all CHI cases experience life-long transmission suppression. If CHI-only
intervention coverage is imperfect, additional EHI interventions can lead to dramatic
improvement. Our results suggest that strategies preventing transmission from both CHI and
EHI cases provide the greatest chance for marked, durable reductions in HIV incidence and
prevalence. Sensitivity analyses in which CHI interventions were assumed to provide even
greater survival benefits, or to start at times more typical of current clinical practice,
provided even greater support for inclusion of interventions during EHI.
Interventions directed toward patients with EHI have unique challenges. While antibody
tests may detect some post-acute EHI cases, a “test-and-treat” approach for specifically
identifying EHI cases would require a very brief interval for repeat testing (~3-6 months),
and reliance on antibody tests would result in missed AHI cases. Large-scale programs of
quarterly or semi-annual HIV testing would be difficult to implement and sustain. Both
biological and behavioural interventions intended for EHI may require more targeted
approaches, such as partner notification or campaigns aimed at encouraging HIV testing
among individuals with recent risky behaviour and acute retroviral symptoms.59 These case-
finding strategies, in combination with pooling of blood samples,47 targeted HIV RNA
screening,48, 60 and/or newer HIV detection tests1, 61 could increase the numbers of EHI
cases detected, even in resource-limited settings. Encouragingly, our best-fitting value of 4·8
months for the period of elevated transmissibility suggests that interventions provided
during the first few months of infection, rather than the first few weeks, may have
substantial public health benefit. In earlier work we demonstrated that the HIV concentration
in seminal plasma remained elevated for more than two months after infection, consistent
with this idea.3
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Interventions initiated during EHI may also have unique benefits that are not explicitly
captured in our model. Adherence to biological or behavioural interventions initiated during
EHI may remain high at least through the most infectious period,50 potentially maximizing
cost-effectiveness and minimizing the detrimental effect of waning adherence observed with
some interventions.62, 63 Additionally, at least some studies suggest a clinical benefit from
initiation of treatment during EHI.64
Mathematical models of HIV transmission depend heavily on assumptions about sexual
behaviour. The input values for sexual behaviour parameters in our model were based on a
cross-sectional study conducted among STD clinic patients in Lilongwe30 that found long-
term monogamy to be common, with only 14% reporting long-term concurrency, sporadic
concurrency, or consecutive, monogamous partnerships in rapid succession. Although based
on a relatively small sample (n=186) with generalizability likely limited to similar settings,
these data represent some of the most detailed information available on partnership
durations and gaps in sub-Saharan Africa. In our best-fitting model simulation, “steady”
partnerships in the higher-risk group were 1.3 months in duration, with intervening gaps of
11 days; by contrast, steady partnership durations and gaps in the lower-risk group were 2.5
years and 1.5 years, respectively. Therefore, the difference between “steady” and “casual”
partners appears to be considerably less distinct for higher-risk than lower-risk individuals,
potentially explaining why some behavioural parameters resulting from the model fit vary in
somewhat unexpected ways across groups. For example, despite the higher casual contact
rate that we initially posited for higher-risk singles, the best-fitting parameter set suggests a
lower rate, possibly because the shorter gap between “steady” partnerships translates to less
time as a single in the high-risk group. We also note that the partner change rate in our
higher-risk group was slower than in the highest-risk groups of several previous HIV
epidemic models,13, 65 and that none of our behavioural parameters was particularly
extreme, despite being collected in an STI clinic population. The latter result may be due to
the high prevalence of STIs in Malawi,66, 67 which likely results in considerable overlap
between STI clinic populations and the “general” population.
The importance of sexual partner concurrency in the HIV epidemic of sub-Saharan Africa
has been emphasized and debated.68-72 Intuitively, concurrency seems potentially important
for transmission during EHI, because long-term monogamy would limit the high
transmissibility of newly infected persons to a single partnership. Our model captured only a
simple form of concurrency – one-off encounters outside of pairs; it did not include long-
term concurrency. However, our best-fitting parameter set included short gaps between
partners (11 days) in a relatively sizeable higher-risk group. These short gap lengths are
consistent with (and based on) our data from Malawi,30 and provide an alternate explanation
for rapid HIV spread and the corresponding importance of EHI; however, the potential
contribution of concurrency cannot be excluded.
All mathematical models have limitations. In our model, individuals and pairs were
restricted to a given risk group, and only a very simple form of concurrency was captured, as
noted above. Additionally, our model did not incorporate population age structure or male-
female behavioural asymmetry. The inclusion of behavioural heterogeneity across two
separate risk groups may capture some age-related behavioural variation, but the results give
an average picture for the sexually active population overall. Nevertheless, our division of
EHI into numerous intervals, our inclusion of more than one risk group, and our
incorporation of both steady and casual contacts likely reflect transmission dynamics more
accurately than previous models that have assumed only one-off contacts occurring at
random within populations. Additional considerations, such as drug resistance, side effects,
behavioural disinhibition, and cost, must also be carefully appraised before implementing
specific treatment-based interventions.
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In summary, our analyses suggest that EHI remains a critical factor in the ongoing HIV
epidemic in Lilongwe. This result suggests that acute and early HIV infection can be
important not only in the earliest phases of HIV epidemics, but also in more mature
epidemics. Consequently, prevention approaches directed at all stages of HIV will likely be
necessary to ensure a durable effect on the epidemic in Lilongwe and similar settings. As
plans for “treatment as prevention” are developed, our results suggest that strategies for
detection and management of patients with acute and early HIV must be included.
Panel: Research in context
Systematic review
In a recent review of mathematical models estimating the contribution of AHI/EHI to
ongoing HIV transmission,73 we noted that estimates have varied widely, due to differences
in epidemic stage, populations studied, model structure, parameter values, and assumptions
in the absence of site-specific data. None of these modelling studies compared the potential
impact of transmission prevention interventions initiated in acute/early HIV versus chronic
infection. Previous modelling studies examining “treatment as prevention” strategies for
established infection19,57,58,65 have had mixed results related to the control of HIV.74
Interpretation
The events that transpire during acute HIV infection are critical to the health of the infected
individual and the health of the public.1 Our study suggests that transmission prevention
interventions achieving intermediate levels of coverage during both early and chronic HIV
will have a far greater impact on the spread of HIV in Malawi than interventions focused on
chronic HIV alone. As such, the population-level impact of “test-and-treat” strategies is
likely to be optimized only if individuals with acute/early HIV are included or if
complementary interventions targeting the earliest phases of infection are incorporated into
the overall prevention approach.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flow diagram of modelling methods
Analyses began with model development (Step 1), followed first by a Bayesian melding
procedure (Steps 2-4) to identify model parameter values most compatible with observed
epidemic dynamics in Lilongwe, and next by estimation of the contribution of EHI and
prediction of intervention effects (Step 5).
* See Figure 2 for schematic of basic model structure and Web Appendix for corresponding
equations.
† See Table 1 for complete listing of model input parameters and corresponding prior
distributions.
‡ See Figure 3 for plot of ANC data and posterior distribution of model simulations
§ See Figure 4 for estimated EHI contribution
** See Figure 5 for predicted intervention effects
Powers et al. Page 15













Figure 2. Simplified diagram of model structure
Unshaded boxes represent single (unpaired) individuals; shaded boxes represent steady
partnerships. As detailed by the accompanying labels, arrows represent flows from one
compartment to another via demographic processes (entering & exiting the population),
partnership formation and dissolution, or HIV transmission. For ease of illustration, the
diagram does not illustrate the two separate risk groups or the multiple stages of infection.
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Figure 3. HIV ANC prevalence data and posterior distribution of output prevalence curves
HIV prevalence data from the sentinel surveillance site in a Lilongwe antenatal clinic are
shown as points, with the corresponding 95% confidence intervals as bracketed vertical
lines. HIV prevalence output generated from the mode (i.e., best-fitting) set of input
parameters is shown as the solid black curve. The dashed curves were generated from the
2·5th and 97·5th percentile values from the entire posterior set of model-produced prevalence
predictions at each time point. The red curve represents the median value at each time point.
Powers et al. Page 17













Figure 4. Estimated proportion of incident HIV infections attributable to contact with EHI index
case
The solid curve represents the annual proportion of incident HIV infections attributable to
contact with an EHI index case predicted by the mode set of input parameters. The dashed
curves correspond to the simulations producing the 2·5th and 97·5th percentile values in the
year 2010.
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Figure 5. Predicted effects of interventions during EHI only, CHI only, or both periods on HIV
prevalence and incidence
HIV prevalence (left panel) and incidence (right panel) in Lilongwe is shown for scenarios
with no intervention (solid black curve) and for interventions initiated in 2010 with various
levels of coverage in early HIV infection (EHI) and/or chronic HIV infection (CHI). The
figures in the top row (5A, 5B) compare the “no-intervention” scenario with “EHI-only”
interventions suppressing transmission in 25%, 50%, 75%, 85%, 90%, 95%, and 100% of
those with EHI. Figures 5C-5F compare the “no-intervention” scenario with “CHI-only”
interventions suppressing transmission in 25%, 50%, 75%, 85%, 90%, 95%, and 100% of
those with CHI; 5C and 5D assume no increase in life expectancy associated with the
intervention, while 5E and 5F assume increased life expectancy associated with the
intervention (see Methods). Figures 5G-5J and 5K-5N compare the “no-intervention”
scenario with four different strategies in which 75% of CHI cases (5G-5J) or 85% of CHI
cases (5K-5N) are reached: one that suppresses transmission only in CHI cases, and three
that also suppress transmission in 25%, 50%, and 75% of EHI cases, respectively. In these
last two sets of figures, 5G, 5H, 5K, and 5L assume no increase in life expectancy associated
with the CHI intervention; 5I, 5J, 5M, and 5N assume increased life expectancy associated
with the CHI intervention (see Methods). All figures are based on input parameters from the
modal simulation.
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Figure 6. Intervention Coverage Levels Required for HIV Elimination in Lilongwe
Predicted levels of coverage required in EHI and/or CHI to result in HIV elimination within
30 years of intervention implementation, assuming (A) no increase in life expectancy
associated with CHI interventions or (B) increased life expectancy associated with CHI
interventions (see Methods). The “Granich definition” requires a reduction in annual HIV
incidence to 1 case per 1000 persons. The “Dahlem definition” requires a reduction in
annual incident cases to 0.
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